93-14-1 Usage
Description
Different sources of media describe the Description of 93-14-1 differently. You can refer to the following data:
1. Guaifenesin is an oral expectorant drug. The expectorant action of guaifenesin is mediated by stimulation of the gastrointestinal tract. It is a common ingredient in prescription and over-the-counter medications used to treat cough due to colds and minor upper respiratory infections.
2. Guaifenesin was originally derived from the guaiac tree and
used by Native Americans for health purposes. Synthesis of
guaifenesin was first reported in 1912. Guaifenesin has
been used in the treatment of respiratory diseases since the
nineteenth century. The United States’ Food and Drug
Administration (FDA) approved guaifenesin for use in overthe-
counter medications in 1989. Guaifenesin is widely
consumed alone and combined with antihistamines, cough
suppressants, and decongestants. Guaifenesin is also a centrally
acting muscle relaxant and is used routinely in combination
with analgesics and sedatives in large-animal veterinary
surgery.
References
[1] Peter V. Dicpinigaitis and Yvonne E. Gayle, Effect of Guaifenesin on Cough Reflex Sensitivity, 2003, vol. 124, 2178-2181
[2] Leonid Kagan, Eran Lavy and Ammon Hoffmann, Effect of mode of administration on guaifenesin pharmacokinetics and expectorant action in the rat model, Pulmonary Pharmacology & Therapeutics, 2009, vol. 22, 260-265
Chemical Properties
White Solid
Originator
GG Cen,Central,US,1975
Uses
Different sources of media describe the Uses of 93-14-1 differently. You can refer to the following data:
1. Centrally acting muscle relaxant with expectorant properties
2. Used to assist the expectoration of phlegm from the airways in acute respiratory tract infections.
3. Guaifenesin is commonly used as an expectorant.
Guaifenesin comes in tablet and capsule form, as syrup, as
dissolving granules, and recently as an extended-release (longacting)
tablet. The tablets, capsules, dissolving granules, and
syrup are usually taken with or without food every 4 h as
needed. The extended-release tablet is usually taken with or
without food every 12 h.
In veterinary medicine, guaifenesin is given intravenously
to induce muscle relaxation when administering anesthesia. It
relaxes both laryngeal and pharyngeal muscles, allowing easier
intubation. Guaifenesin is also used in the treatment of horses
with exertional rhabdomyolysis and in dogs with strychnine
intoxication.
Manufacturing Process
A mixture of o-methoxyphenol (57 g), glycidol (32 g) and pyridine (1 g) is
warmed to 95°C at which temperature a vigorous reaction takes place. The
reaction mixture is cooled to prevent the temperature rising above 110°C.
When the exothermic reaction has subsided the reactants are heated at 95°C
for one hour longer and then distilled under low pressure. The main fraction
boils in the range 176°C to 180°C/0.5 mm. It crystallizes on cooling.
Recrystallization from benzene gives the pure product, MP 78.5°C to 79.0°C.
Brand name
Mucinex (Adams).
General Description
Guaifenesin is an expectorant, widely used in the treatment of cough. Its mode of action involves the alleviating of cough discomfort by increasing sputum volume and decreasing its viscosity, thus resulting in effective cough.Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Mechanism of action
Guaiphenesin facilitates secretion from bronchial mucous membranes, thus relieving a
cough in colds, bronchitis, and bronchial asthma.
Synthesis
Guaiphenesin, 3-(o-methoxyphenoxy)-1,2-propandiol (23.2.3), is synthesized
by reacting guiacol with 3-chloropropan-1,2-diol or with glycidol.
Veterinary Drugs and Treatments
In veterinary medicine, guaifenesin is used to induce muscle relaxation
and restraint
as an adjunct to anesthesia for short procedures
(30 – 60 minutes) in large and small animal species. There are combination
oral products containing guaifenesin for treating respiratory
conditions in horses.
In human medicine, guaifenesin has long been touted as an oral
expectorant, but definitive proof of its efficacy is lacking.
Environmental Fate
Guaifenesin’s production and use as veterinary and human
medicines may result in its release to the environment through
various waste streams.
If released to air, an estimated vapor pressure of
1.5× 10–6 mm Hg at 25 ℃ indicates that guaifenesin will
exist in both the vapor and particulate phase.
Based upon an estimated Henry’s law constant of
4.4 × 10-11 atm-m3 mol-1, volatilization from moist soil
surfaces or from water surfaces are not expected to be important
fate processes for guaifenesin.
Guaifenesin is expected to have high mobility in soil based
upon an organic carbon–water partition coefficient (Koc) of
140, which indicates that it will have more solubility in water
and is less likely to adsorb onto organic matter in soil and
plants.
Toxicity evaluation
Guaifenesin is an adrenergic antagonist in a class of medications
called expectorants. It stimulates afferent receptors in the
gastric mucosa, reflexively increasing glandular secretion by the
respiratory epithelium promoting lower respiratory tract
drainage by thinning bronchial secretions, lubricating irritated
respiratory tract membranes through increased mucous flow,
and facilitating removal of viscous mucus. The onset of action
appears to be within 15–30 min. Guaifenesin is believed to
alleviate cough discomfort by improving sinus and bronchial
drainage, increasing sputum volume, and decreasing sputum
viscosity, thereby promoting effective cough. In one study, the
effect of guaifenesin to increase mucociliary clearance from the
lung was greater in patients with chronic bronchitis than in
healthy subjects.
In another study, guaifenesin inhibited the cough reflex
sensitivity in subjects with an upper respiratory tract infection
(cough receptors are transiently hypersensitive), but not in
healthy volunteers. Possible mechanisms include a central
antitussive effect or a peripheral effect by increased sputum
volume serving as a physical barrier, shielding cough receptors
within the respiratory epithelium.
As a centrally acting muscle relaxant, guaifenesin is believed
to depress or block nerve impulse transmission at the internuncial
neuron level of the subcortical areas of the brain, brain
stem, and spinal cord. It also has mild analgesic and sedative
actions.
Check Digit Verification of cas no
The CAS Registry Mumber 93-14-1 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 9 and 3 respectively; the second part has 2 digits, 1 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 93-14:
(4*9)+(3*3)+(2*1)+(1*4)=51
51 % 10 = 1
So 93-14-1 is a valid CAS Registry Number.
InChI:InChI=1/C10H14O4/c1-13-9-4-2-3-5-10(9)14-7-8(12)6-11/h2-5,8,11-12H,6-7H2,1H3/t8-/m0/s1
93-14-1Relevant articles and documents
Trapping of muscle relaxant methocarbamol degradation product by complexation with copper(II) ion: Spectroscopic and quantum chemical studies
Mansour, Ahmed M.,Shehab, Ola R.
, p. 263 - 271 (2014)
Structural properties of methocarbamol (Mcm) were extensively studied both experimentally and theoretically using FT IR, 1H NMR, UV-Vis., geometry optimization, Mulliken charge, and molecular electrostatic potential. Stability arises from hyper
Ligand-Free Copper-Catalyzed Ullmann-Type C?O Bond Formation in Non-Innocent Deep Eutectic Solvents under Aerobic Conditions
Capriati, Vito,García-álvarez, Joaquín,Marinò, Manuela,Perna, Filippo M.,Quivelli, Andrea Francesca,Vitale, Paola
, (2021/12/09)
An efficient and novel protocol was developed for a Cu-catalyzed Ullmann-type aryl alkyl ether synthesis by reacting various (hetero)aryl halides (Cl, Br, I) with alcohols as active components of environmentally benign choline chloride-based eutectic mixtures. Under optimized conditions, the reaction proceeded under mild conditions (80 °C) in air, in the absence of additional ligands, with a catalyst [CuI or CuII species] loading up to 5 mol% and K2CO3 as the base, providing the desired aryloxy derivatives in up to 98 % yield. The potential application of the methodology was demonstrated in the valorization of cheap, easily available, and naturally occurring polyols (e. g., glycerol) for the synthesis of some pharmacologically active aryloxypropanediols (Guaiphenesin, Mephenesin, and Chlorphenesin) on a 2 g scale in 70–96 % yield. Catalyst, base, and deep eutectic solvent could easily and successfully be recycled up to seven times with an E-factor as low as 5.76.
Glycerol as a source of designer solvents: Physicochemical properties of low melting mixtures containing glycerol ethers and ammonium salts
Leal-Duaso, Alejandro,Pérez, Pascual,Mayoral, José A.,Pires, Elisabet,García, José I.
, p. 28302 - 28312 (2017/11/06)
In this work we report the preparation of mixtures of several alkyl glyceryl ethers, as hydrogen bond donor compounds, with two ammonium salts, choline chloride and N,N,N-triethyl-2,3-dihydroxypropan-1-aminium chloride. The stability of the mixtures at different molar ratios and temperatures has been evaluated in order to determine the formation of low melting mixtures. Liquid and stable mixtures have been characterized and their physico-chemical properties such as density, viscosity, refractive index, conductivity and surface tension have been measured in the temperature range of 293.15 K to 343.15 K. Comparison of the mixtures prepared herein with the ones containing glycerol and choline chloride evidences the possibility of tuning the physico-chemical properties by changing the substitution pattern in the hydrogen bond donor compound or in the ammonium salt, thus broadening the scope of application of these mixtures.
